GeoVax and Sino Biological collaborates for COVID-19 Vaccine

▴ geovax-and-sino-biological-research-collaboration-covid19-vaccine
More companies are joining hands against coronavirus,race to develop the vaccine is on !

GeoVax Labs, Inc.,a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced today that Beijing- and Philadelphia-based Sino Biological, Inc. will be its exclusive supplier of SARS-Cov-2 (COVID-19) bioreagent research products.

Under the terms of the agreement, Sino Biological will provide key bioreagents such as recombinant proteins, antibodies and detection kits for use in COVID-19 vaccine development underway at GeoVax. Sino Biological will also obtain exclusive rights to research-use-only (RUO) reagents developed jointly by the companies. Financial terms were not disclosed. Sino Biological was the first to market with mammalian cell-made COVID-19 viral recombinant proteins and offers a full range of these and other bioreagents to complement and aid in COVID-19 vaccine development and has the world’s largest selection of coronavirus research-grade products. GeoVax is at the forefront of development for a COVID-19 vaccine and its use of recombinant viruses to generate virus-like particles (VLPs) in vivo has demonstrated considerable immune response for other viruses in a number of human clinical trials.

Commenting on the exclusive partnership, David A. Dodd, GeoVax Chairman& CEO stated, “We are delighted to establish this collaboration with Sino Biological related to our COVID-19 vaccine development program. Sino Biological is recognized as the research reagent industry leader in developing and providing COVID-19 bioreagent research products, as well as a leader throughout the bioreagent research industry. We look forward to further expansion of our relationship with Sino Biological, including our agreement related to research-use-only (RUO) reagents.”

“GeoVax’s unique VLP-generation technology is exciting, and its commitment to the development of a vaccine for COVID-19 is inspiring. We at Sino Biological are honored to be the exclusive provider of COVID-19-related research reagents to assist their vaccine development efforts.”, commented Rob Burgess, Ph.D., Chief Business Officer for Sino Biological.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using a novel proprietary vaccine platform (GV-MVA-VLPTM). On this platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into VLP immunogens within the person receiving the vaccine(in vivo). The production of VLPs in the person being vaccinated mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. The GV-MVA-VLPTMderived vaccines can elicit durable immune responses in the host similar to a live-attenuated virus, while typically providing the safety characteristics of a replication-defective vector.

GeoVax’s current development programs are focused on preventive vaccines against COVID-19, HIV, Zika, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and malaria, as well as therapeutic vaccines against chronic Hepatitis B infections and multiple cancers. The Company has developed preventive HIV vaccine candidates (GOVX-B11) for the clade B subtype of HIV prevalent in the Americas, Western Europe, Japan, and Australia, and the clade C subtype prevalent in Africa and India. GOVX-B11is scheduled for inclusion in an upcoming human clinical trial managed by the HVTN with the support of the National Institutes of Health (NIH). GeoVax’s clade B HIV vaccine is also part of collaborative efforts to develop immunotherapy as a functional cure for HIV.

Tags : #Geovax #SinoBiological #Covidvaccine #Reagents

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Sexual wellness superstore, Love Depot launches digital campaign to deliver every desireMarch 28, 2024
Recharge Your Life: Simple Ways to Boost Your Physical and Mental EnergyMarch 28, 2024
The Neurological Toll of Common Household Chemicals: Insights from Recent ResearchMarch 28, 2024
The Aging Puzzle: Decoding the Mechanisms of AgingMarch 28, 2024
The Double-Edged Sword of Kala-azar Treatment: Shedding Light on Eye ComplicationsMarch 28, 2024
FTCCI Launches Industry-Academia Connect to improve the employability of Engineering Graduates and address the growing demand for Talent in Emerging TechMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
2nd Edition of IIFL JITO Ahimsa Run for peace & for non-violence to be held on 31st MarchMarch 27, 2024
Brij Hotels Announced 4 Million in Series A Funding March 27, 2024
Combatting Childhood Sedentariness: The Key to Preventing Premature Vascular DamageMarch 27, 2024
Crucial Findings: Unlocking Paths to Combat Ebola's DevastationMarch 27, 2024
Guarding Against Disease: The Crucial Role of Oral Hygiene in Preventive HealthcareMarch 27, 2024
Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in IndiaMarch 26, 2024
Surmandal's Tribute to the Legends of Hindustani Classical MusicMarch 26, 2024
In Moscow, over 350,000 mammograms have been analyzed using artificial intelligence as part of the compulsory health insurance programMarch 26, 2024
Embark on a Creative Journey: "Kala For A Cause" Unveils Pottery Workshop Series March 26, 2024
Healthtech pioneer Aurora Innovation appoints new CEO – expands in Europe with service that streamlines patient-healthcare interactionMarch 26, 2024
In A Rare Feat, 45 YO Woman Walks Within 6 Hrs. Of Dual Robotic Surgery In A Single Operation At HCGMCCMarch 26, 2024
Improve Cancer Care through Automated CT Analysis: Oncoshield – CTMarch 26, 2024